|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAH11 |
Gene summary for DNAH11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAH11 | Gene ID | 8701 |
| Gene name | dynein axonemal heavy chain 11 | |
| Gene Alias | CILD7 | |
| Cytomap | 7p15.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | H9NAJ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8701 | DNAH11 | AEH-subject1 | Human | Endometrium | AEH | 3.74e-02 | 1.75e-01 | -0.3059 |
| 8701 | DNAH11 | AEH-subject2 | Human | Endometrium | AEH | 5.92e-04 | 2.57e-01 | -0.2525 |
| 8701 | DNAH11 | AEH-subject3 | Human | Endometrium | AEH | 6.96e-06 | 2.81e-01 | -0.2576 |
| 8701 | DNAH11 | AEH-subject4 | Human | Endometrium | AEH | 4.55e-26 | 8.06e-01 | -0.2657 |
| 8701 | DNAH11 | AEH-subject5 | Human | Endometrium | AEH | 3.66e-08 | 3.57e-01 | -0.2953 |
| 8701 | DNAH11 | EEC-subject2 | Human | Endometrium | EEC | 2.45e-20 | 5.66e-01 | -0.2607 |
| 8701 | DNAH11 | EEC-subject4 | Human | Endometrium | EEC | 6.28e-04 | 3.10e-01 | -0.2571 |
| 8701 | DNAH11 | TD9 | Human | Lung | IAC | 1.26e-09 | 1.01e+00 | 0.088 |
| 8701 | DNAH11 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.28e-05 | 7.75e-01 | 0.343 |
| 8701 | DNAH11 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 5.29e-01 | 0.3385 |
| 8701 | DNAH11 | RNA-P17T-P17T-8 | Human | Lung | IAC | 4.12e-03 | 4.94e-01 | 0.3329 |
| 8701 | DNAH11 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.35e-14 | 8.50e-01 | 0.1829 |
| 8701 | DNAH11 | RNA-P3T-P3T-2 | Human | Lung | IAC | 4.73e-12 | 7.71e-01 | 0.1835 |
| 8701 | DNAH11 | RNA-P3T-P3T-4 | Human | Lung | IAC | 1.04e-14 | 8.64e-01 | 0.1859 |
| 8701 | DNAH11 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 2.66e-09 | 1.15e+00 | -0.0238 |
| 8701 | DNAH11 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 5.44e-06 | 9.27e-01 | -0.0186 |
| 8701 | DNAH11 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 6.04e-07 | 1.03e+00 | -0.0296 |
| 8701 | DNAH11 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 1.92e-13 | 1.22e+00 | -0.0263 |
| 8701 | DNAH11 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.12e-03 | 2.00e-01 | -0.0132 |
| 8701 | DNAH11 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 4.39e-01 | -0.0961 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00030072 | Endometrium | AEH | heart morphogenesis | 45/2100 | 246/18723 | 6.41e-04 | 6.23e-03 | 45 |
| GO:00032062 | Endometrium | AEH | cardiac chamber morphogenesis | 23/2100 | 121/18723 | 7.76e-03 | 4.33e-02 | 23 |
| GO:00030071 | Endometrium | EEC | heart morphogenesis | 45/2168 | 246/18723 | 1.24e-03 | 1.03e-02 | 45 |
| GO:0099111 | Lung | IAC | microtubule-based transport | 35/2061 | 190/18723 | 1.55e-03 | 1.64e-02 | 35 |
| GO:00328861 | Lung | MIAC | regulation of microtubule-based process | 23/967 | 240/18723 | 3.27e-03 | 4.31e-02 | 23 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501620 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
| hsa0501420 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
| hsa0502220 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
| hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa05016110 | Endometrium | AEH | Huntington disease | 118/1197 | 306/8465 | 3.00e-27 | 2.44e-25 | 1.78e-25 | 118 |
| hsa05014110 | Endometrium | AEH | Amyotrophic lateral sclerosis | 123/1197 | 364/8465 | 2.17e-22 | 7.82e-21 | 5.72e-21 | 123 |
| hsa05022110 | Endometrium | AEH | Pathways of neurodegeneration - multiple diseases | 137/1197 | 476/8465 | 9.27e-18 | 2.32e-16 | 1.70e-16 | 137 |
| hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
| hsa0501625 | Endometrium | EEC | Huntington disease | 120/1237 | 306/8465 | 3.86e-27 | 4.23e-25 | 3.15e-25 | 120 |
| hsa0501425 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
| hsa0502225 | Endometrium | EEC | Pathways of neurodegeneration - multiple diseases | 140/1237 | 476/8465 | 9.49e-18 | 2.60e-16 | 1.94e-16 | 140 |
| hsa048142 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| hsa0501635 | Endometrium | EEC | Huntington disease | 120/1237 | 306/8465 | 3.86e-27 | 4.23e-25 | 3.15e-25 | 120 |
| hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
| hsa0502235 | Endometrium | EEC | Pathways of neurodegeneration - multiple diseases | 140/1237 | 476/8465 | 9.49e-18 | 2.60e-16 | 1.94e-16 | 140 |
| hsa048143 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
| hsa04814 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| hsa048141 | Lung | MIAC | Motor proteins | 21/507 | 193/8465 | 5.64e-03 | 3.82e-02 | 2.76e-02 | 21 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAH11 | SNV | Missense_Mutation | novel | c.12032N>A | p.Gly4011Glu | p.G4011E | Q96DT5 | protein_coding | tolerated(0.18) | benign(0.044) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| DNAH11 | SNV | Missense_Mutation | novel | c.12032N>A | p.Gly4011Glu | p.G4011E | Q96DT5 | protein_coding | tolerated(0.18) | benign(0.044) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| DNAH11 | SNV | Missense_Mutation | novel | c.10596N>T | p.Leu3532Phe | p.L3532F | Q96DT5 | protein_coding | deleterious(0.01) | benign(0.134) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| DNAH11 | SNV | Missense_Mutation | c.9100N>A | p.Glu3034Lys | p.E3034K | Q96DT5 | protein_coding | tolerated(0.09) | benign(0.31) | TCGA-A8-A07O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | ||
| DNAH11 | SNV | Missense_Mutation | c.3010N>C | p.Asp1004His | p.D1004H | Q96DT5 | protein_coding | deleterious(0.04) | probably_damaging(0.964) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DNAH11 | SNV | Missense_Mutation | c.9617N>G | p.Lys3206Arg | p.K3206R | Q96DT5 | protein_coding | tolerated(0.1) | possibly_damaging(0.767) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| DNAH11 | SNV | Missense_Mutation | rs752884953 | c.13177A>G | p.Met4393Val | p.M4393V | Q96DT5 | protein_coding | tolerated(0.1) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAH11 | SNV | Missense_Mutation | c.10159N>C | p.Glu3387Gln | p.E3387Q | Q96DT5 | protein_coding | tolerated(0.07) | benign(0.401) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DNAH11 | SNV | Missense_Mutation | novel | c.12769G>T | p.Asp4257Tyr | p.D4257Y | Q96DT5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| DNAH11 | SNV | Missense_Mutation | rs751896015 | c.4334N>A | p.Arg1445Gln | p.R1445Q | Q96DT5 | protein_coding | tolerated(0.13) | benign(0.02) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |